Glucotrack to showcase CBGM at ADCES Annual Meeting in Phoenix.
ByAinvest
Thursday, Jul 31, 2025 8:40 am ET1min read
GCTK--
The ADCES Annual Meeting is a premier event that brings together leading experts in diabetes care and education to discuss new insights within the diabetes space. Glucotrack's participation provides an excellent opportunity to engage with key stakeholders and share the latest developments in continuous blood glucose monitoring technology.
Glucotrack's CBGM represents a significant advancement in diabetes management, offering a fully implantable solution that lasts up to three years. Unlike traditional CGMs that measure glucose in interstitial fluid through skin-worn devices, this system measures glucose directly from blood without requiring any external wearables. This approach addresses key limitations of current CGM technology, including the need for frequent sensor changes and the challenges associated with on-body wearables.
The company is preparing to begin its long-term early feasibility study following successful initial clinical validation. Glucotrack's CBGM is an Investigational Device and is limited by federal law to investigational use. The company aims to advance its technology towards a US pilot study, with the ultimate goal of improving the quality of life for people living with diabetes.
The poster presentation, titled "Endocrinologists’ Perspectives on an Implantable Continuous Blood Glucose Monitor," will be held on Saturday, August 9, from 12:00 PM to 1:00 PM MST. The session will provide insights into physician perspectives regarding the potential benefits and challenges of implantable continuous glucose monitoring technology.
For more information about Glucotrack’s CBGM, visit [Glucotrack's website](http://www.glucotrack.com).
References:
[1] https://www.globenewswire.com/news-release/2025/07/31/3124984/0/en/Glucotrack-to-Exhibit-at-2025-Association-of-Diabetes-Care-and-Education-Specialists-Annual-Meeting.html
[2] https://www.stocktitan.net/news/GCTK/glucotrack-to-exhibit-at-2025-association-of-diabetes-care-and-whrvv67xs5rl.html
Glucotrack, a medical device company focused on diabetes technology, will participate in the Association of Diabetes Care and Education Specialists' Annual Meeting in Phoenix, AZ. The company will showcase its Continuous Blood Glucose Monitor (CBGM) at Booth #1724 and present a poster on physician perspectives regarding the technology. The ADCES conference brings together experts in diabetes care and education to discuss new insights in the field.
Glucotrack, Inc. (Nasdaq: GCTK), a medical device company specializing in diabetes technology, has announced its participation in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting, to be held from August 8-11, 2025, in Phoenix, AZ. The company will showcase its innovative Continuous Blood Glucose Monitor (CBGM) at Booth #1724 and present a scientific poster on endocrinologist perspectives regarding implantable monitoring technology.The ADCES Annual Meeting is a premier event that brings together leading experts in diabetes care and education to discuss new insights within the diabetes space. Glucotrack's participation provides an excellent opportunity to engage with key stakeholders and share the latest developments in continuous blood glucose monitoring technology.
Glucotrack's CBGM represents a significant advancement in diabetes management, offering a fully implantable solution that lasts up to three years. Unlike traditional CGMs that measure glucose in interstitial fluid through skin-worn devices, this system measures glucose directly from blood without requiring any external wearables. This approach addresses key limitations of current CGM technology, including the need for frequent sensor changes and the challenges associated with on-body wearables.
The company is preparing to begin its long-term early feasibility study following successful initial clinical validation. Glucotrack's CBGM is an Investigational Device and is limited by federal law to investigational use. The company aims to advance its technology towards a US pilot study, with the ultimate goal of improving the quality of life for people living with diabetes.
The poster presentation, titled "Endocrinologists’ Perspectives on an Implantable Continuous Blood Glucose Monitor," will be held on Saturday, August 9, from 12:00 PM to 1:00 PM MST. The session will provide insights into physician perspectives regarding the potential benefits and challenges of implantable continuous glucose monitoring technology.
For more information about Glucotrack’s CBGM, visit [Glucotrack's website](http://www.glucotrack.com).
References:
[1] https://www.globenewswire.com/news-release/2025/07/31/3124984/0/en/Glucotrack-to-Exhibit-at-2025-Association-of-Diabetes-Care-and-Education-Specialists-Annual-Meeting.html
[2] https://www.stocktitan.net/news/GCTK/glucotrack-to-exhibit-at-2025-association-of-diabetes-care-and-whrvv67xs5rl.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet